Cancer immunotherapy can lose its effectiveness when the T cells deployed to attack tumors become exhausted, but researchers at Memorial Sloan Kettering Cancer Center may have found a way to keep those cells fighting longer. The team identified a signaling molecule called MEK that pushes T cells to burn through their energy reserves while they produce the proteins that kill cancer cells.
In animal and laboratory studies, blocking MEK allowed the T cells to conserve energy, survive longer, and remain active even in the harsh environment that surrounds tumors. The finding points to a potential strategy for improving cell-based cancer treatments, which have transformed care for some blood cancers but often falter in solid tumors where the immune cells quickly wear out.
T cell exhaustion is a well-known obstacle in immunotherapy. When T cells are repeatedly stimulated by tumor cells, they can enter a state of dysfunction marked by reduced proliferation, weakened killing capacity, and altered metabolism. The Sloan Kettering work suggests that MEK signaling is one of the metabolic switches that accelerates this decline.
By interfering with that signal, the researchers were able to shift the cells toward a more durable state. The T cells retained their cancer-killing function for longer periods in the studies, which involved both animal models and laboratory experiments. The results add to a growing body of research aimed at making immunotherapy more persistent, particularly for patients whose tumors do not respond to current treatments.
The research remains at the preclinical stage, and it is not yet clear whether blocking MEK in patients would produce the same benefits without unwanted side effects. MEK is part of a signaling pathway involved in cell growth and division, and drugs that target it are already used in some cancer therapies. That existing knowledge could help speed the translation of the findings into clinical testing, but further studies will be needed to determine whether the approach is safe and effective in people.
If the strategy holds up, it could offer a new way to extend the usefulness of T cell therapies. Rather than engineering T cells to recognize new targets, the approach would help the cells already present in a patient or used in treatment resist the metabolic exhaustion that limits their lifespan. That could make immunotherapy more reliable across a wider range of cancers.
The research was conducted at Memorial Sloan Kettering Cancer Center and focused on the role of MEK in T cell metabolism. The findings were reported in animal and laboratory studies, and the next steps would involve testing whether MEK inhibition can be safely combined with existing immunotherapies.
10
